A Phase I Investigation of the Combination of MK2206, Trastuzumab and Lapatinib in HER2+ Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2015
At a glance
- Drugs MK 2206 (Primary) ; Lapatinib; Trastuzumab
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck & Co
- 06 Mar 2012 Actual patients number changed from 33 to 31 as reported by ClinicalTrials.gov.
- 09 Feb 2012 Actual end date changed from Aug 2011 to Dec 2011 as reported by ClinicalTrials.gov.
- 26 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.